Concepts (200)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Drug Overdose | 10 | 2023 | 65 | 4.590 |
Why?
|
| Opioid-Related Disorders | 12 | 2023 | 161 | 3.190 |
Why?
|
| Analgesics, Opioid | 14 | 2024 | 413 | 1.910 |
Why?
|
| Drug Users | 4 | 2024 | 19 | 1.600 |
Why?
|
| Pharmaceutical Preparations | 2 | 2022 | 92 | 1.460 |
Why?
|
| Substance Abuse, Intravenous | 3 | 2023 | 54 | 1.310 |
Why?
|
| Harm Reduction | 4 | 2024 | 16 | 1.210 |
Why?
|
| HIV Infections | 11 | 2023 | 772 | 1.190 |
Why?
|
| Substance-Related Disorders | 4 | 2024 | 394 | 1.120 |
Why?
|
| Rural Population | 8 | 2023 | 136 | 1.070 |
Why?
|
| Naloxone | 5 | 2023 | 59 | 1.050 |
Why?
|
| Hepatitis C, Chronic | 3 | 2015 | 126 | 1.050 |
Why?
|
| Hepatitis C | 3 | 2023 | 208 | 1.040 |
Why?
|
| Chromatin | 2 | 2023 | 380 | 0.970 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 581 | 0.950 |
Why?
|
| Fentanyl | 3 | 2023 | 65 | 0.930 |
Why?
|
| Buprenorphine | 2 | 2023 | 33 | 0.880 |
Why?
|
| Pandemics | 8 | 2023 | 740 | 0.870 |
Why?
|
| Actins | 2 | 2023 | 451 | 0.800 |
Why?
|
| Mentoring | 1 | 2021 | 30 | 0.750 |
Why?
|
| Betacoronavirus | 2 | 2020 | 258 | 0.750 |
Why?
|
| Coinfection | 3 | 2021 | 58 | 0.750 |
Why?
|
| Prescription Drug Misuse | 1 | 2020 | 13 | 0.720 |
Why?
|
| Narcotic Antagonists | 3 | 2021 | 154 | 0.710 |
Why?
|
| Prescriptions | 1 | 2019 | 21 | 0.700 |
Why?
|
| Heroin | 1 | 2019 | 11 | 0.680 |
Why?
|
| Drug Utilization | 1 | 2019 | 65 | 0.670 |
Why?
|
| Hepacivirus | 2 | 2023 | 159 | 0.660 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 301 | 0.650 |
Why?
|
| Hospital Mortality | 1 | 2020 | 349 | 0.640 |
Why?
|
| Uridine Monophosphate | 2 | 2015 | 9 | 0.630 |
Why?
|
| Illinois | 5 | 2023 | 462 | 0.620 |
Why?
|
| Tuberculosis, Pulmonary | 2 | 2015 | 58 | 0.610 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2019 | 238 | 0.560 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 316 | 0.550 |
Why?
|
| Drug Therapy | 1 | 2015 | 70 | 0.520 |
Why?
|
| Ribavirin | 2 | 2015 | 57 | 0.520 |
Why?
|
| Humans | 43 | 2024 | 86617 | 0.510 |
Why?
|
| Drug Costs | 2 | 2017 | 62 | 0.500 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 26 | 0.500 |
Why?
|
| Antiviral Agents | 2 | 2015 | 510 | 0.500 |
Why?
|
| Tuberculosis | 2 | 2012 | 110 | 0.480 |
Why?
|
| Obesity | 1 | 2020 | 963 | 0.470 |
Why?
|
| Sulfonamides | 1 | 2014 | 300 | 0.420 |
Why?
|
| Cost-Benefit Analysis | 6 | 2021 | 451 | 0.420 |
Why?
|
| Methamphetamine | 2 | 2023 | 82 | 0.410 |
Why?
|
| United States | 8 | 2023 | 6665 | 0.400 |
Why?
|
| Social Stigma | 3 | 2020 | 52 | 0.400 |
Why?
|
| Adult | 17 | 2023 | 25640 | 0.370 |
Why?
|
| Male | 20 | 2023 | 40958 | 0.360 |
Why?
|
| Chromoblastomycosis | 1 | 2009 | 2 | 0.360 |
Why?
|
| Buttocks | 1 | 2009 | 10 | 0.360 |
Why?
|
| Ascomycota | 1 | 2009 | 16 | 0.350 |
Why?
|
| Exanthema | 1 | 2009 | 36 | 0.340 |
Why?
|
| Middle Aged | 14 | 2020 | 25017 | 0.330 |
Why?
|
| Female | 19 | 2023 | 44509 | 0.320 |
Why?
|
| Retrospective Studies | 8 | 2021 | 8477 | 0.290 |
Why?
|
| Sexual and Gender Minorities | 3 | 2020 | 192 | 0.290 |
Why?
|
| Skin | 1 | 2009 | 554 | 0.270 |
Why?
|
| Cell Nucleus | 2 | 2023 | 579 | 0.250 |
Why?
|
| Chicago | 5 | 2020 | 1379 | 0.250 |
Why?
|
| Lamin Type A | 1 | 2023 | 24 | 0.240 |
Why?
|
| Attitude | 2 | 2024 | 127 | 0.240 |
Why?
|
| RNA Polymerase II | 1 | 2023 | 55 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 2 | 2023 | 30 | 0.230 |
Why?
|
| Ethambutol | 2 | 2012 | 6 | 0.220 |
Why?
|
| Antifungal Agents | 2 | 2017 | 117 | 0.220 |
Why?
|
| Isoniazid | 2 | 2012 | 8 | 0.220 |
Why?
|
| Social Networking | 2 | 2020 | 75 | 0.210 |
Why?
|
| Risk Factors | 4 | 2020 | 5417 | 0.200 |
Why?
|
| Cohort Studies | 3 | 2019 | 2767 | 0.200 |
Why?
|
| Case Management | 1 | 2021 | 24 | 0.200 |
Why?
|
| Rural Health Services | 1 | 2020 | 13 | 0.190 |
Why?
|
| Aged | 6 | 2020 | 18402 | 0.190 |
Why?
|
| Social Norms | 1 | 2019 | 9 | 0.180 |
Why?
|
| Quality of Life | 2 | 2020 | 1583 | 0.180 |
Why?
|
| Aged, 80 and over | 4 | 2019 | 6501 | 0.180 |
Why?
|
| Gram-Negative Bacteria | 1 | 2019 | 35 | 0.180 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2019 | 23 | 0.180 |
Why?
|
| Public Health Practice | 1 | 2019 | 11 | 0.170 |
Why?
|
| Homosexuality, Male | 2 | 2020 | 298 | 0.170 |
Why?
|
| Point-of-Care Systems | 2 | 2021 | 141 | 0.170 |
Why?
|
| Longitudinal Studies | 2 | 2019 | 1019 | 0.170 |
Why?
|
| Bacteremia | 1 | 2019 | 99 | 0.160 |
Why?
|
| Disease Outbreaks | 1 | 2019 | 154 | 0.160 |
Why?
|
| Odds Ratio | 1 | 2020 | 678 | 0.160 |
Why?
|
| Treatment Outcome | 6 | 2020 | 7990 | 0.160 |
Why?
|
| Cross Infection | 1 | 2019 | 141 | 0.160 |
Why?
|
| Sofosbuvir | 2 | 2015 | 18 | 0.160 |
Why?
|
| Delivery of Health Care | 1 | 2022 | 426 | 0.160 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 379 | 0.160 |
Why?
|
| Public Health | 1 | 2019 | 129 | 0.150 |
Why?
|
| Patient Participation | 1 | 2019 | 216 | 0.150 |
Why?
|
| Directly Observed Therapy | 1 | 2017 | 5 | 0.150 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 6 | 0.150 |
Why?
|
| Phosphorylcholine | 1 | 2017 | 28 | 0.150 |
Why?
|
| Nystatin | 1 | 2017 | 2 | 0.150 |
Why?
|
| Meglumine | 1 | 2017 | 39 | 0.150 |
Why?
|
| Gentian Violet | 1 | 2017 | 10 | 0.150 |
Why?
|
| Antiprotozoal Agents | 1 | 2017 | 33 | 0.150 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2017 | 52 | 0.150 |
Why?
|
| Candidiasis, Oral | 1 | 2017 | 4 | 0.150 |
Why?
|
| Comorbidity | 1 | 2020 | 943 | 0.140 |
Why?
|
| Students, Medical | 1 | 2021 | 384 | 0.140 |
Why?
|
| Time Factors | 3 | 2015 | 5209 | 0.140 |
Why?
|
| Organometallic Compounds | 1 | 2017 | 132 | 0.140 |
Why?
|
| Renal Dialysis | 1 | 2019 | 355 | 0.140 |
Why?
|
| Health Behavior | 1 | 2017 | 183 | 0.140 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 746 | 0.140 |
Why?
|
| AIDS Serodiagnosis | 1 | 2016 | 25 | 0.140 |
Why?
|
| Diagnostic Equipment | 1 | 2015 | 3 | 0.130 |
Why?
|
| Uganda | 1 | 2015 | 34 | 0.130 |
Why?
|
| India | 2 | 2012 | 120 | 0.130 |
Why?
|
| Life Expectancy | 1 | 2015 | 86 | 0.130 |
Why?
|
| Health Facilities | 1 | 2015 | 38 | 0.130 |
Why?
|
| Simeprevir | 1 | 2014 | 4 | 0.130 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2015 | 103 | 0.120 |
Why?
|
| Age Factors | 1 | 2019 | 1849 | 0.120 |
Why?
|
| Continuity of Patient Care | 1 | 2016 | 169 | 0.120 |
Why?
|
| Needs Assessment | 1 | 2015 | 154 | 0.120 |
Why?
|
| Incidence | 3 | 2013 | 1577 | 0.120 |
Why?
|
| Antitubercular Agents | 1 | 2012 | 52 | 0.110 |
Why?
|
| Models, Economic | 1 | 2012 | 60 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2017 | 1991 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 370 | 0.100 |
Why?
|
| Prevalence | 1 | 2015 | 1239 | 0.100 |
Why?
|
| Anti-HIV Agents | 1 | 2013 | 149 | 0.090 |
Why?
|
| Decision Making | 1 | 2016 | 642 | 0.090 |
Why?
|
| Itraconazole | 1 | 2009 | 11 | 0.090 |
Why?
|
| Cryotherapy | 1 | 2009 | 29 | 0.090 |
Why?
|
| Young Adult | 5 | 2020 | 5974 | 0.090 |
Why?
|
| China | 1 | 2009 | 228 | 0.080 |
Why?
|
| Physicians | 1 | 2016 | 673 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2023 | 1621 | 0.080 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 484 | 0.080 |
Why?
|
| CD4 Lymphocyte Count | 2 | 2020 | 66 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1169 | 0.070 |
Why?
|
| Monte Carlo Method | 2 | 2017 | 185 | 0.070 |
Why?
|
| Reproducibility of Results | 1 | 2012 | 2705 | 0.070 |
Why?
|
| Hospitalization | 2 | 2021 | 849 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2017 | 684 | 0.070 |
Why?
|
| Adolescent | 4 | 2019 | 8979 | 0.060 |
Why?
|
| Needle-Exchange Programs | 1 | 2023 | 18 | 0.060 |
Why?
|
| Methadone | 1 | 2023 | 36 | 0.060 |
Why?
|
| Data Collection | 1 | 2023 | 372 | 0.050 |
Why?
|
| Pneumonia, Bacterial | 1 | 2021 | 28 | 0.050 |
Why?
|
| Antimicrobial Stewardship | 1 | 2021 | 21 | 0.050 |
Why?
|
| Jurisprudence | 1 | 2021 | 25 | 0.050 |
Why?
|
| Community-Acquired Infections | 1 | 2021 | 63 | 0.050 |
Why?
|
| Community Networks | 1 | 2021 | 29 | 0.050 |
Why?
|
| HIV Seropositivity | 1 | 2020 | 49 | 0.050 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 10 | 0.050 |
Why?
|
| Azithromycin | 1 | 2020 | 13 | 0.050 |
Why?
|
| Criminal Law | 1 | 2020 | 11 | 0.050 |
Why?
|
| Cephalosporins | 1 | 2020 | 24 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2020 | 41 | 0.050 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 64 | 0.050 |
Why?
|
| Geographic Information Systems | 1 | 2019 | 20 | 0.040 |
Why?
|
| Outpatients | 1 | 2019 | 94 | 0.040 |
Why?
|
| Transcription, Genetic | 1 | 2023 | 1135 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2019 | 319 | 0.040 |
Why?
|
| Mental Health | 1 | 2019 | 162 | 0.040 |
Why?
|
| Pilot Projects | 1 | 2021 | 839 | 0.040 |
Why?
|
| Inpatients | 1 | 2021 | 297 | 0.040 |
Why?
|
| Socioeconomic Factors | 1 | 2020 | 567 | 0.040 |
Why?
|
| Leishmania | 1 | 2017 | 7 | 0.040 |
Why?
|
| Injections, Intramuscular | 1 | 2017 | 62 | 0.040 |
Why?
|
| Social Isolation | 1 | 2017 | 67 | 0.040 |
Why?
|
| Administration, Topical | 1 | 2017 | 95 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 153 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2020 | 394 | 0.040 |
Why?
|
| Stereotyping | 1 | 2016 | 13 | 0.040 |
Why?
|
| Health Communication | 1 | 2016 | 13 | 0.040 |
Why?
|
| Delayed Diagnosis | 1 | 2016 | 29 | 0.040 |
Why?
|
| Culture | 1 | 2016 | 53 | 0.030 |
Why?
|
| Mass Screening | 1 | 2020 | 617 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2016 | 73 | 0.030 |
Why?
|
| Caregivers | 1 | 2017 | 151 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 360 | 0.030 |
Why?
|
| Markov Chains | 1 | 2015 | 125 | 0.030 |
Why?
|
| Health Care Costs | 1 | 2017 | 237 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2015 | 138 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1139 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 199 | 0.030 |
Why?
|
| Interferon-alpha | 1 | 2015 | 233 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2021 | 1034 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2015 | 297 | 0.030 |
Why?
|
| Nigeria | 1 | 2013 | 152 | 0.030 |
Why?
|
| Viral Load | 1 | 2013 | 148 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 3636 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 1801 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2012 | 916 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 610 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 860 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 858 | 0.020 |
Why?
|
| Disease Progression | 1 | 2015 | 1531 | 0.020 |
Why?
|
| Genotype | 1 | 2015 | 1851 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2017 | 3611 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2501 | 0.020 |
Why?
|
| Child | 1 | 2017 | 6926 | 0.020 |
Why?
|